151 related articles for article (PubMed ID: 30233667)
1. Impact of phosphorylated insulin-like growth factor-1 receptor on the outcome of breast cancer patients and the prognostic value of its alteration during neoadjuvant chemotherapy.
Li L; Liu S; Liu L; Ma Z; Feng M; Ye C; Zhou W; Wang Y; Liu L; Wang F; Yu L; Zhou F; Xiang Y; Huang S; Fu Q; Zhang Q; Gao D; Yu Z
Exp Ther Med; 2018 Oct; 16(4):2949-2959. PubMed ID: 30233667
[TBL] [Abstract][Full Text] [Related]
2. The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis.
Yan S; Jiao X; Li K; Li W; Zou H
Onco Targets Ther; 2015; 8():279-87. PubMed ID: 25674003
[TBL] [Abstract][Full Text] [Related]
3. Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Pijl H; Charehbili A; van de Ven S; Smit VTHBM; Meershoek-Klein Kranenbarg E; Heijns JB; van Warmerdam LJC; Kessels LW; Dercksen MW; Pepels MJAE; van Laarhoven HWM; Vriens BEPJ; Putter H; Fiocco M; Liefers GJ; van der Hoeven JJM; Nortier JWR; Kroep JR;
Breast Cancer Res; 2019 Aug; 21(1):97. PubMed ID: 31455425
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.
Bhargava R; Beriwal S; McManus K; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):218-25. PubMed ID: 21217522
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Wauters CA; Strobbe LJ; Mandigers CM; Bult P; Oyen WJ; van der Graaf WT; van Laarhoven HW
PLoS One; 2015; 10(2):e0117745. PubMed ID: 25680198
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
de Groot S; Charehbili A; van Laarhoven HW; Mooyaart AL; Dekker-Ensink NG; van de Ven S; Janssen LG; Swen JJ; Smit VT; Heijns JB; Kessels LW; van der Straaten T; Böhringer S; Gelderblom H; van der Hoeven JJ; Guchelaar HJ; Pijl H; Kroep JR;
Breast Cancer Res; 2016 Jan; 18(1):3. PubMed ID: 26738606
[TBL] [Abstract][Full Text] [Related]
7. Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.
Shin SJ; Gong G; Lee HJ; Kang J; Bae YK; Lee A; Cho EY; Lee JS; Suh KS; Lee DW; Jung WH
J Breast Cancer; 2014 Jun; 17(2):113-20. PubMed ID: 25013431
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.
Yerushalmi R; Gelmon KA; Leung S; Gao D; Cheang M; Pollak M; Turashvili G; Gilks BC; Kennecke H
Breast Cancer Res Treat; 2012 Feb; 132(1):131-42. PubMed ID: 21574055
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor 1 receptor expression in breast cancer tissue and mammographic density.
Sun WY; Yun HY; Song YJ; Kim H; Lee OJ; Nam SJ; Koo JS
Mol Clin Oncol; 2015 May; 3(3):572-580. PubMed ID: 26137269
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis.
Shimizu C; Hasegawa T; Tani Y; Takahashi F; Takeuchi M; Watanabe T; Ando M; Katsumata N; Fujiwara Y
Hum Pathol; 2004 Dec; 35(12):1537-42. PubMed ID: 15619214
[TBL] [Abstract][Full Text] [Related]
12. Impact of epidermal growth factor receptor, mesenchymal-epithelial transition factor, and insulin-like growth factor receptor 1 expression on survival of patients with oral and oropharyngeal cancer.
Perisanidis C; Wrba F; Brandstetter A; Kornek G; Mitchell D; Seemann R; Selzer E; Ewers R; Filipits M
Br J Oral Maxillofac Surg; 2013 Apr; 51(3):234-40. PubMed ID: 22889668
[TBL] [Abstract][Full Text] [Related]
13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
Christodoulou C; Oikonomopoulos G; Koliou GA; Kostopoulos I; Kotoula V; Bobos M; Pentheroudakis G; Lazaridis G; Skondra M; Chrisafi S; Koutras A; Bafaloukos D; Razis E; Papadopoulou K; Papakostas P; Kalofonos HP; Pectasides D; Skarlos P; Kalogeras KT; Fountzilas G
Cancer Genomics Proteomics; 2018; 15(6):461-471. PubMed ID: 30343280
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Gradishar WJ; Yardley DA; Layman R; Sparano JA; Chuang E; Northfelt DW; Schwartz GN; Youssoufian H; Tang S; Novosiadly R; Forest A; Nguyen TS; Cosaert J; Grebennik D; Haluska P
Clin Cancer Res; 2016 Jan; 22(2):301-9. PubMed ID: 26324738
[TBL] [Abstract][Full Text] [Related]
18. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
Cornelissen B; McLarty K; Kersemans V; Reilly RM
Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab.
Fujita N; Enomoto Y; Inakami K; Yanagisawa T; Iguchi C; Aono T; Nomura T; Yamamoto H; Kasugai T; Shiba E
Oncology; 2020; 98(1):35-41. PubMed ID: 31574500
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue.
Chong YM; Colston K; Jiang WG; Sharma AK; Mokbel K
Breast Cancer Res Treat; 2006 Oct; 99(3):275-88. PubMed ID: 16752221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
